Mark Couch, Author at Colorado Cancer Blogs

Richard Schulick Named Director of University of Colorado Cancer Center

by Mark Couch | Jun 7, 2018 | Featured, Latest News, Patient Care, Research

Richard D. Schulick, MD, MBA, a renowned cancer surgeon and accomplished administrative leader, has been named director of the University of Colorado Cancer Center to lead a $100 million investment in the program over the next five years. The University of Colorado...

Discontinuing statins for patients with life limiting illnesses, including cancer

by Mark Couch | Mar 25, 2015 | Patient Care

Discontinuing statin use in patients with advanced-stage cancer and other terminal illnesses may help improve patients’ quality of life without causing other adverse health effects, according to a new study led by researchers at the University of Colorado Anschutz...

@CUCancerCenter on Twitter

@CUCancerCenter 26 mins

Tarloxotinib, originally meant to target HER2/EGFR cancers, also shows promise in cancers with NRG1-fusion. This co… twitter.com/i/web/status/1…
@CUCancerCenter 3 hours

Melanomas are "hot" or "cold". "Hot" melanomas light up when treated w/ immunotherapy, making it easier for the im… twitter.com/i/web/status/1…
@CUCancerCenter 4 hours

AACR: Tobacco use makes precancerous cells that "fertilize" cancer growth Full story: bit.ly/2uBxaf6… twitter.com/i/web/status/1…
@CUCancerCenter 5 hours

The Colorado Cancer Wellness Conference is returning on September 14th! Come to discuss cancer nutrition, cancer ex… twitter.com/i/web/status/1…
@CUCancerCenter April 22, 2019

5000 (and counting) participants are enrolled in the ORIEN program at our cancer center! Thank you for accelerating… twitter.com/i/web/status/1…
@CUCancerCenter April 22, 2019

Despite being preventable, colorectal cancer is the 2nd leading cause of cancer related death in the USA. Here is w… twitter.com/i/web/status/1…
@CUCancerCenter April 22, 2019

We are thrilled to be part of #ORIEN! Please check out this quick video about our involvement in the program!… twitter.com/i/web/status/1…
@CUCancerCenter April 22, 2019

CU Cancer Center study finds that the combination of chemo drug Irinotecan and experimental drug AZD0156 work bette… twitter.com/i/web/status/1…
@CUCancerCenter April 22, 2019

Tarloxotinib "very promising" against NRG1-fusion cancers. Although the mutation is rare, drug could help ~3,500 pa… twitter.com/i/web/status/1…
@CUCancerCenter April 22, 2019

New from AACR: Adavosertib speeds cancer cells into the wall of mitotic catastrophe bit.ly/2Kdxj2O… twitter.com/i/web/status/1…
@CUCancerCenter April 22, 2019

Healthline named our blog one of the top cancer blogs of 2019! This is the third time we have made this list! Full… twitter.com/i/web/status/1…
@CUCancerCenter April 22, 2019

New study suggests a way to ensure that cancer cells with damaged DNA fly past G2M to their doom: Blindfold the rac… twitter.com/i/web/status/1…